Accordingly, to assess the differential drugs effect on normal cell viability alongside, a set of three ARPE-19-hTERT cell lines in WT, FANCA.KO, FANCC.KO genetic backgrounds, as well as the FA-HNSCC- matched normal cell lines, VU1131-CAF and VU1604-CAF, were included in the drug dose–response assays. The gene discussed is FANCC; the disease is head and neck squamous cell carcinoma.